A human granin-like neuroendocrine peptide precursor (proSAAS) immunoreactivity in tau inclusions of Alzheimer's disease and parkinsonism–dementia complex on Guam
Section snippets
Acknowledgements
The authors thank Dr L.D. Fricker, Albert Einstein College of Medicine, for providing the anti-N- and C-proSAAS antibodies.
References (11)
- et al.
Functional characterization of ProSAAS: similarities and differences with 7B2
J. Biol. Chem.
(2002) - et al.
A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease
Am. J. Pathol.
(1999) PHF and PHF-like fibrils – cause or consequence?
Neurobiol. Aging
(2001)- et al.
An N-terminal fragment of proSAAS (a human granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease
Biochem. Biophys. Res. Commun.
(2003) - et al.
Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer's disease patients
Mol. Brain Res.
(1994)
Cited by (22)
Extracellular chaperone networks and the export of J-domain proteins
2023, Journal of Biological ChemistryAge-associated changes in microglia and astrocytes ameliorate blood-brain barrier dysfunction
2021, Molecular Therapy Nucleic AcidsCitation Excerpt :ProSAAS, encoded by gene Pcsk1n, an abundant secretory polypeptide that is widely expressed in the human, mouse, and rat brain, regulates the proteolytic cleavage of neuroendocrine peptide precursors. ProSAAS has been widely suggested to colocalize with Lewy bodies or amyloid plaques and carry out chaperone anti-aggregant functions in AD, Pick’s disease, and Parkinsonism-dementia (Figure 10),42–47 contribute to the physiological effects of psychostimulants,48 and serve as a therapeutic agent in the case of food-intake disorders49,50 as well as a cerebrospinal fluid biomarker in AD and frontotemporal dementia.51,52 It has been previously reported that Pcsk1n expression was upregulated in the hippocampus of rats with more severe BBB disruption;53 however, the role of ProSAAS in BBB regulation in mice has remained obscure.
Granins as disease-biomarkers: Translational potential for psychiatric and neurological disorders
2010, NeuroscienceCitation Excerpt :In addition to neurological, psychiatric and clinical diagnoses, altered levels of tau and amyloid fragments in CSF are routinely used for diagnostic purposes, although their diagnostic performance is not optimal with regard to specificity (Blennow et al., 2006; Sonnen et al., 2008). Several studies identified increased CgA, SgII and ProSAAS, in post-mortem filament aggregates in tauopathies (Weiler et al., 1990; Munoz, 1991; Kikuchi et al., 2003; Wada et al., 2004; Lechner et al., 2004), and one proteomic study identified a decreased CgA level in the CSF of canonical but not late onset Type II (Kamboh, 2004) Alzheimer's disease patients (Blennow et al., 1995, but see O'Connor et al., 1993). More recently, several proteomic studies have confirmed the potential utility of granin fragments as candidate diagnostic biomarkers for tauopathies.
Ubiquitination and cysteine nitrosylation during aging and Alzheimer's disease
2009, Brain Research BulletinSynaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex
2022, Acta Neuropathologica CommunicationsSequestration of TDP-43<sup>216-414</sup>Aggregates by Cytoplasmic Expression of the proSAAS Chaperone
2022, ACS Chemical Neuroscience